Edition:
United States

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

1.79USD
4:00pm EDT
Change (% chg)

$-0.08 (-4.28%)
Prev Close
$1.87
Open
$1.89
Day's High
$1.91
Day's Low
$1.77
Volume
69,448
Avg. Vol
189,136
52-wk High
$9.55
52-wk Low
$1.51

Chart for

About

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $92.60
Shares Outstanding(Mil.): 52.31
Dividend: --
Yield (%): --

Financials

  ADXS.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -2.37 -- --
ROI: -106.00 -8.07 12.63
ROE: -132.09 -10.87 14.50

BRIEF-Advaxis Announces Executive Leadership Changes

* ADVAXIS INC - KENNETH BERLIN HAS BEEN APPOINTED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Apr 23 2018

BRIEF-Advaxis Reports Q1 Loss Per Share $0.49

* ADVAXIS REPORTS FISCAL 2018 FIRST QUARTER FINANCIAL RESULTS AND ANNOUNCES CLINICAL HOLD IN AXALIMOGENE FILOLISBAC PHASE 1/2 COMBINATION STUDY WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB)

Mar 12 2018

BRIEF-Advaxis Prices $20.0 Mln Public Offering Of Common Stock

* ADVAXIS PRICES $20.0 MILLION PUBLIC OFFERING OF COMMON STOCK

Feb 22 2018

BRIEF-Advaxis Announces Proposed Public Offering Of Common Stock

* ADVAXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

Feb 21 2018

BRIEF-Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31

* ADVAXIS INC SAYS EXPECTS TO REPORT THAT IT HAD $59.4 MILLION OF CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JANUARY 31, 2018 - SEC FILING Source text: (http://bit.ly/2BHztlx) Further company coverage:

Feb 21 2018

BRIEF-Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union

* ADVAXIS SUBMITS CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR AXALIMOGENE FILOLISBAC FOR THE SECOND-LINE TREATMENT OF METASTATIC CERVICAL CANCER IN EUROPEAN UNION

Feb 13 2018

BRIEF-Advaxis Says Expects Its Current Cash Position Will Be Sufficient To Fund Its Business Plan Into Fiscal 2019

* ADVAXIS REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

Dec 20 2017

Earnings vs. Estimates